Status:
COMPLETED
Personalized CRT - MPP Post Approval Study
Lead Sponsor:
Medtronic
Conditions:
Heart Failure
Eligibility:
All Genders
Brief Summary
The purpose of this Post-Approval Study (PAS) is to evaluate the effectiveness of MPP to improve CRT response in the non-responder patient population when used in "real-world" clinical practice, follo...
Detailed Description
Medtronic market-released cardiac resynchronization therapy (CRT) Quadripolar (Quad) systems approved for commercial release with the Multiple Point Pacing (MPP) feature were eligible to contribute to...
Eligibility Criteria
Inclusion
- Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
- Patient has or is intended to receive or be treated with an eligible CRT device
- Patient within 30 days of therapy received at the time of their initial PSR platform enrollment
Exclusion
- Patient who is, or is expected to be inaccessible for follow-up
- Patient with exclusion criteria required by local law
- Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
Key Trial Info
Start Date :
July 5 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 7 2021
Estimated Enrollment :
1338 Patients enrolled
Trial Details
Trial ID
NCT03232944
Start Date
July 5 2017
End Date
January 7 2021
Last Update
February 17 2021
Active Locations (78)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-0001
2
Saint Vincent Heart Clinic Arkansas
Little Rock, Arkansas, United States, 72205-6202
3
Chula Vista Cardiac Center
Chula Vista, California, United States, 91910
4
Desert Heart Rhythm Consultants
Palm Springs, California, United States, 92262